Chronic Kidney Disease, Type 2 Diabetes
Conditions
Keywords
Metformin, type 2 diabetes, chronic kidney disease, antidiabetic medications, lactic acidosis
Brief summary
Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit. Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients. The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.
Interventions
OTHERmodalities of metformin prescription
Metformin prescription or not, in each CKD stage
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years old or more * Type 2 diabetes * Seen by a nephrologist (consultation or hospitalization) between March 2014 and March 2020 in the Department of Nephrology, Lyon Sud university hospital, France
Exclusion criteria
* On-going treatment by dialysis * Kidney transplantation * Type 1 diabetes * Missing data (metformin treatment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients receiving metformin | every January 1st up to 2020 | metformin use during chronic kidney disease. Percentage of patients receiving metformin will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of reasons for non-prescription of metformin | every January 1st up to 2020 | metformin use during chronic kidney disease. Occurence of reasons for non-prescription of metformin will be recorded. |
| CKD stages | every January 1st up to 2020 | CKD stages will be recorded. |
| Dose of metformin | every January 1st up to 2020 | metformin use during chronic kidney disease. Dose of metformin will be recorded. |
| starting time of insulin | every January 1st up to 2020 | need for insulin |
| occurrence of lactic acidosis | every January 1st up to 2020 | data file analysis and record of lactic acidosis episodes |
| Doses of oral antidiabetes medications | every January 1st up to 2020 | Oral antidiabetic medications use during chronic kidney disease. Doses of oral antidiabetes medications (sulfonylureas, alpha-glucosidase inhibitors, Dipeptidyl peptidase-4 (DPP4) inhibitors, incretin mimetics, SGLT2 inhibitors) will be recorded. |
Countries
France
Contacts
Primary ContactDenis FOUQUE, MD PhD
Outcome results
None listed